|Bid||90.33 x 900|
|Ask||90.38 x 1300|
|Day's Range||90.25 - 91.06|
|52 Week Range||71.91 - 93.65|
|Beta (3Y Monthly)||0.55|
|PE Ratio (TTM)||17.11|
|Forward Dividend & Yield||2.83 (3.18%)|
|1y Target Est||99.50|
Novartis (NVS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Mallinckrodt (MNK) halts its phase IIB study, assessing the efficacy and safety of Acthar Gel as an investigational treatment for amyotrophic lateral sclerosis.
Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%. Now let's see what investors should expect heading into its Q2 2019 earnings release on Thursday.
Investors will focus on regular top- and bottom-line numbers along with pipeline updates when Novartis (NVS) reports second-quarter results.
Japanese drugmaker Eisai is investing $120 million over three years in an Alzheimer's research center — a 20 percent increase over the funding Eisai originally had allocated for the facility.
The FDA accepts Novartis' (NVS) BLA for crizanlizumab and grants Priority Review to the same to prevent pain crises in patients with sickle cell disease.
Eton's (ETON) partner receives complete response letter for a regulatory application seeking approval of its pipeline candidate, EM-100, as a treatment for ocular itching.
The U.S. Justice Department is reportedly pursuing a criminal investigation as to whether J&J (JNJ) lied about the possible cancer risk associated with its talcum powder.
GlaxoSmithKline is to hire Jonathan Symonds, a former finance director at rival drugmakers AstraZeneca and Novartis, as its new chairman to oversee a break-up of the UK pharmaceuticals group. The appointment of Mr Symonds, who is currently deputy group chairman of HSBC, will end a six-month search for a replacement for Sir Philip Hampton, who has been non-executive chairman of GSK since 2015. Mr Symonds has extensive experience of the pharmaceutical industry.
Amgen (AMGN) and Novartis (NVS) discontinue two Alzheimer's disease studies. Alzheimer's has always been a highly challenging area with many studies failing.
A drug to treat Alzheimer's disease is increasingly proving elusive, despite billions of dollars spent on research and development. Johnson & Johnson (NYSE: JNJ )'s Janssen unit; Merck & Co., Inc. (NYSE: ...
Aimmune's (AIMT) peanut allergy candidate AR101 attracts negative review from ICER, stating risks outweighs benefits in patients. AR101 is under review and a decision is expected by January 2020.
Dow Jones futures: Illumina stock and profitable marijuana stock Innovative Industrial Properties fell late on news. An Amgen-Novartis Alzheimer's drug failed. Hookipa Pharma soared.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on July 11) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) GALAPAGOS ...
Amgen Inc. and Novartis AG announced Thursday afternoon that they will discontinue a study into a potential Alzheimer's disease prevention therapy after patients in the study showed worsening conditions. "An assessment of unblinded data during a regular pre-planned review identified worsening in some measures of cognitive function," the companies said in a joint announcement. "The sponsors concluded that the potential benefit for participants in the studies did not outweigh the risk." The phase 2/3 study, performed in conjunction with Banner Alzheimer's Institute, was testing the BACE1 inhibitor CNP520, or umibecestat, which is an amyloid-focused drug. Biogen Inc. failed in testing of an amyloid-focused drug earlier this year, leading some to predict that focusing on the sticky protein found in the brain could be a losing route to a drug for the debilitating neurodegenerative disease. "We still believe amyloid plays an important but complex role in Alzheimer's disease," Amgen executive David Reese said in Thursday's announcement. Novartis shares were down 1.5% in after-hours trading Thursday, while Amgen shares were not moving after the announcement.
Amgen and Novartis have closed two studies trying to find drugs for Alzheimer’s disease, dealing another blow to the millions of patients left waiting for a treatment for the neurodegenerative disorder. The pharmaceutical companies, along with their partner, the research centre Banner Alzheimer’s Institute, said that some patients on the trials had shown a worsening — rather than the hoped for improvement — in cognitive function. The decision comes after Biogen, a neuroscience-focused biotech company, closed down its Alzheimer’s drug trial with Japanese company Eisai in April, after they found the drug was not going to be effective.
Glaxo's (GSK) phase III study, evaluating the efficacy of switching to Dovato from a three-drug TAF based regimen, meets the primary endpoint.
A collaboration with Swiss pharma giant Novartis could validate an experimental cancer treatment from biotech company Mirati Therapeutics, an analyst said Wednesday as Mirati stock rose.
It looks like there is no end is sight to the EpiPen shortage and Mylan (NASDAQ:MYL) stock is taking a beating Wednesday on the news.Source: Shutterstock Recent statements from the company note that it continues to expect the EpiPen shortage to continue. This is leaving many parents without a way to purchase the medicine as they prepare for the next school season to begin.The reason behind the EpiPen shortage is that the company had production issues back in 2017. Following these problems, the U.S. Food & Drug Administration (FDA) announced that there was a shortage of the devices in the following year. The FDA still has EpiPens listed as in short supply.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSo what exactly can parents do to get around the EpiPen shortage? There's always the option of going with the generic version of the drug, which is also made by Mylan. The FDA does not list this one as being limited in supply.Another option that parents may want to consider are rival products. This includes those made by Teva Pharmaceutical (NYSE:TEVA) or Novartis (NYSE:NVS). However, there are concerns about the difference in using these devices and them not being as recognizable as normal EpiPens, reports Bloomberg. * 7 Retail Stocks to Buy for the Second Half of 2019 The Novartis option may be the best one for parents on a budget. The company is selling a two-pack of adult dosage syringes for $250. This is below the $300 price for a comparable pack of Mylan's generic version, Reuters notes.MYL stock was down 3% as of noon Wednesday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy on College Students' Radars * 7 Retail Stocks to Buy for the Second Half of 2019 * The S&P 500's 5 Best Highest-Yielding Dividend Stocks As of this writing, William White did not hold a position in any of the aforementioned securities.The post EpiPen Shortage: Mylan (MYL) Stock Falls on Continued Scarce Supply appeared first on InvestorPlace.